TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24275625

Group type: EXPERIMENTAL
Intervention: Split toric lenses misaligned by 0°, 5° or 10°
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Split toric lenses misaligned around 180°
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Split toric power misaligned with low cylinder
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Split toric power misaligned with high cylinder
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Adapted astigmats with split toric power misaligned
Number of subjects: 2
Study: 19465507

Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 48
Study: 15182276

Group type: EXPERIMENTAL
Intervention: BUD + M group (400 microg/day of inhaled budesonide plus 10 mg/day of montelukast)
Number of subjects: 30

Group type: COMPARATOR
Intervention: High BUD group (800 microg/day of inhaled budesonide)
Number of subjects: 30
Study: 11263112

Group type: EXPERIMENTAL
Intervention: Strength training (n = 19)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Active control (group walk session, n = 25)
Number of subjects: 44
Study: 9239584

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etomidate (0.1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sufentanil/N2O anesthesia
Number of subjects: 0
Study: 8107484

Group type: EXPERIMENTAL
Intervention: Exercise (on a bicycle ergometer or treadmill) to self-imposed maximum
Number of subjects: 10

Group type: COMPARATOR
Intervention: Quiet rest in a soundproof chamber
Number of subjects: 10
Study: 3302251

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (multivitamin/multimineral) at high and low dosage
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31665732

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex, 15 Hz, twice daily, 5 days/week for 2 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 8
Study: 30962311

Group type: EXPERIMENTAL
Intervention: Simulation-based education program
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Peer assessment
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Post-intervention survey
Number of subjects: 333
Study: 30068721

Group type: EXPERIMENTAL
Intervention: Delirium assessment completed
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Positive delirium screen results
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Patients always assessed vs never assessed
Number of subjects: 160

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 160
Study: 26186609

Group type: EXPERIMENTAL
Intervention: High adherence (level 1)
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Suboptimal adherence (level 2)
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Suboptimal adherence (level 3)
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Suboptimal adherence (level 4)
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Suboptimal adherence (level 5)
Number of subjects: 1986

Group type: COMPARATOR
Intervention: Suboptimal adherence
Number of subjects: 1986
Study: 24219767

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI) for 9 months in addition to usual services
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual services only
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 150
Study: 21858663

Group type: EXPERIMENTAL
Intervention: Combined treatment (tamsulosin + potassium citrate)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Uralyt‐U(®) (potassium citrate)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 19280794

Group type: EXPERIMENTAL
Intervention: Ultrasonography of median nerve
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (normal wrists)
Number of subjects: 150
Study: 17509197

Group type: EXPERIMENTAL
Intervention: TSPY gene copy number in infertile men
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: TSPY/AMELY ratio
Number of subjects: 124

Group type: COMPARATOR
Intervention: Repeated studies of TSPY copy number
Number of subjects: 124
Study: 15477693

Group type: EXPERIMENTAL
Intervention: Intramuscular octreotide LAR (20 mg initially, increased to 30 mg after 3 injections if mean GH levels >5 mU/l) administered every 28 days for 6 months
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide (50, 100 and 200 mug) administered in a randomized order on separate days prior to LAR therapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intramuscular octreotide LAR
Number of subjects: 6
Study: 11518355

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Surgery and methisoprinol
Number of subjects: 25
Study: 9631159

Group type: EXPERIMENTAL
Intervention: Incentive group (financial incentives of $.80 or $1.60 per shot based on immunization rates)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Incentive group
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 7884757

Group type: EXPERIMENTAL
Intervention: 50 g of a glucose polymer
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: d‐glucose
Number of subjects: 108

Group type: COMPARATOR
Intervention: candy bar
Number of subjects: 108
Study: 3204243

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice containing 1,100 ppm F as sodium fluoride
Number of subjects: 810

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 810
Study: 29696155

Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) principles used for recruitment
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Baseline characteristics of participants
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Uniform approach to implementing a trial or intervention
Number of subjects: 483
Study: 26072052

Group type: EXPERIMENTAL
Intervention: Artificial pancreas without carbohydrate-counting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Artificial pancreas with carbohydrate-counting
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional pump therapy
Number of subjects: 12
Study: 25656621

Group type: EXPERIMENTAL
Intervention: Maraviroc 150 mg daily plus lopinavir/ritonavir (MVC group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine plus lopinavir/ritonavir (TDF/FTC group)
Number of subjects: 50
Study: 23743581

Group type: EXPERIMENTAL
Intervention: Varus alignment of the uninjured knee at follow-up
Number of subjects: 100
Study: 21911950

Group type: EXPERIMENTAL
Intervention: Antibacterial paste containing ciprofloxacin, metronidazole, and minocycline (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Antibacterial paste containing ciprofloxacin, ornidazole, and minocycline mixed with propylene glycol (Group B)
Number of subjects: 40
Study: 18211302

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg extended release
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 16741761

Group type: EXPERIMENTAL
Intervention: Rutland/Patlak method
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: AUC method
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both methods in agreement
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Age < 1 year
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Age > 1 year
Number of subjects: 101
Study: 14662283

Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 534

Group type: COMPARATOR
Intervention: Composite material
Number of subjects: 534
Study: 10735921

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg at 08:00 hours for 14 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg at 22:00 hours for 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both omeprazole and ranitidine
Number of subjects: 60
Study: 8957205

Group type: EXPERIMENTAL
Intervention: 200 micrograms of hCRH
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 400 micrograms of TRH
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0.9% NaCl (control)
Number of subjects: 18
Study: 1539141

Group type: COMPARATOR
Intervention: 200 micrograms salbutamol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 48 micrograms formoterol
Number of subjects: 14
Study: 4034850

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (2 mg intravenous bolus)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (2 mg intravenous bolus) with estrogen (intramuscular 17-beta-estradiol)
Number of subjects: 35
Study: 30585341

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis NCC2818 (1.5 x 10^10 CFU/d)
Number of subjects: 75
Study: 29855371

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) model with descriptive norm and action planning
Number of subjects: 2551
Study: 27600467

Group type: EXPERIMENTAL
Intervention: Active ankle movements in addition to routine nursing
Number of subjects: 193

Group type: COMPARATOR
Intervention: Routine nursing (Control)
Number of subjects: 193
Study: 23906186

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) at a dose of 1.0 μg/kg over 10 min followed by a continuous infusion of 0.5 μg/kg per hour
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sufentanil (SUF) target controlled infusion with a target plasma concentration of 0.3 ng/mL
Number of subjects: 40
Study: 22977271

Group type: EXPERIMENTAL
Intervention: Higher baseline free thyroxine (FT(4)) levels (16.5 ± 2.2 pmol/liter)
Number of subjects: 3401

Group type: EXPERIMENTAL
Intervention: Higher FT(4) levels
Number of subjects: 3401

Group type: EXPERIMENTAL
Intervention: Higher FT(4) levels in euthyroid men
Number of subjects: 3401

Group type: COMPARATOR
Intervention: TSH quartiles
Number of subjects: 3401
Study: 19967325

Group type: EXPERIMENTAL
Intervention: Ergonomic intervention
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control for physical workload and ergonomic workstation design
Number of subjects: 165
Study: 18032268

Group type: EXPERIMENTAL
Intervention: 8-session structured multidisciplinary intervention
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 115
Study: 16046831

Group type: EXPERIMENTAL
Intervention: 7.5% povidone iodine (PVI group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate (CHG group)
Number of subjects: 22
Study: 12154100

Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg, increasing to 100 mg if required) once daily for 8 weeks
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study: 10321482

Group type: EXPERIMENTAL
Intervention: Leftward moving cube
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rightward moving cube
Number of subjects: 0
Study: 7884097

Group type: EXPERIMENTAL
Intervention: Oral pirenzepine (25 mg twice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2104624

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg, iv)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg, orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dexamethasone (4 mg, iv) + Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dexamethasone (4 mg, iv) + Atropine (0.5 mg, iv)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dexamethasone (4 mg, iv) + Pyridostigmine (120 mg, orally)
Number of subjects: 8
Study: 356578

Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine (300 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (no lidocaine)
Number of subjects: 300
Study: 30904515

Group type: EXPERIMENTAL
Intervention: Real injection (hypertonic saline)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham injection (no skin piercing)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 30
Study: 28236348

Group type: EXPERIMENTAL
Intervention: Fixed time interval administration of tramadol, paracetamol, and diclofenac
Number of subjects: 200

Group type: COMPARATOR
Intervention: On-demand administration of tramadol, paracetamol, and diclofenac
Number of subjects: 200
Study: 25749494

Group type: EXPERIMENTAL
Intervention: Specialist respiratory physiotherapists
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-respiratory on-call physiotherapists
Number of subjects: 93
Study: 23315447

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sham acupuncture (S)
Number of subjects: 56
Study: 21299392

Group type: EXPERIMENTAL
Intervention: Distributed interactive learning via web-based modules
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (passive counterpart)
Number of subjects: 181
Study: 19972660

Group type: EXPERIMENTAL
Intervention: Within-dimension conditions (2D/2D or 3D/3D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cross-dimension conditions (3D/2D or 2D/3D)
Number of subjects: 0
Study: 17115874

Group type: EXPERIMENTAL
Intervention: High blood alcohol concentration (BAC) of .10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High blood alcohol concentration (BAC) of .08%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instructions to maximize arousal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instructions to suppress arousal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sober men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intoxicated men
Number of subjects: 0
Study: 15041715

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (35 mg/m(2))
Number of subjects: 46

Group type: COMPARATOR
Intervention: 3-weekly docetaxel (60 mg/m(2) with doxorubicin)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 3-weekly docetaxel (75 mg/m(2))
Number of subjects: 46

Group type: COMPARATOR
Intervention: 3-weekly docetaxel (100 mg/m(2))
Number of subjects: 46
Study: 11106052

Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen lysine (10 mg/kg, followed by 5 mg/kg after 24 and 48 h) within 24 h of life (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous ibuprofen lysine (10 mg/kg, followed by 5 mg/kg after 24 and 48 h) after echocardiographic diagnosis of PDA (group B)
Number of subjects: 80
Study: 9300962

Group type: EXPERIMENTAL
Intervention: Isocentric Reciprocal Gait Orthosis (IRGO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Walkabout Orthosis (WO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both orthoses (IRGO and WO)
Number of subjects: 10
Study: 8358406

Group type: EXPERIMENTAL
Intervention: methylphenidate (0.3 mg/kg b.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 3511581

Group type: EXPERIMENTAL
Intervention: Cyclosporine-prednisone
Number of subjects: 158

Group type: COMPARATOR
Intervention: ALG-azathioprine-prednisone
Number of subjects: 158
Study: 2829613

Group type: EXPERIMENTAL
Intervention: High fiber meal
Number of subjects: 13
Study: 31253691

Group type: EXPERIMENTAL
Intervention: Stent Retrievers (SR)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Contact Aspiration (CA)
Number of subjects: 188
Study: 30844973

Group type: EXPERIMENTAL
Intervention: Normocaloric low-fiber diet
Number of subjects: 276

Group type: COMPARATOR
Intervention: Clear-liquid diet
Number of subjects: 276
Study: 27650531

Group type: EXPERIMENTAL
Intervention: Huber Motion Lab (HML)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional strength training (TST)
Number of subjects: 50
Study: 26062741

Group type: EXPERIMENTAL
Intervention: Social Cognitive Training (SCT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Theory of Mind Intervention (ToMI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 75
Study: 23464904

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRI lesion present
Number of subjects: 50
Study: 21283971

Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 19375893

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone 120 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16392145

Group type: EXPERIMENTAL
Intervention: CO(2) laser resurfacing
Number of subjects: 27

Group type: COMPARATOR
Intervention: IPL rejuvenation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study: 15454388

Group type: EXPERIMENTAL
Intervention: Cut and sew procedure
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency (RF)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Unipolar RF
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cryothermy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Traditional maze III
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Left-sided maze
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Overall surgical procedures
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Continuous AF
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Paroxysmal AF
Number of subjects: 79
Study: 10657894

Group type: EXPERIMENTAL
Intervention: Dissonance-based targeted preventive intervention (three sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed-intervention control condition
Number of subjects: 30
Study: 9596909

Group type: EXPERIMENTAL
Intervention: Lateral posture during labor
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 7901267

Group type: EXPERIMENTAL
Intervention: Protective agent during short-term NSAID use
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Misoprostol for chronic NSAID use
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ranitidine for chronic NSAID use
Number of subjects: 19
Study: 3096643

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (Transiderm‐Nitro 25 mg/24 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30033816

Group type: COMPARATOR
Intervention: Standardized recovery intervals (30 seconds)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Self-selected recovery intervals
Number of subjects: 28
Study: 26859343

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2,000 IU/day)
Number of subjects: 218
Study: 25515221

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (three times/week, 30 min, 70% VO(2) max; n = 24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low intensity physical activity (n = 23)
Number of subjects: 47
Study: 23533227

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (2 doses targeting either 400-550 ng/dL or 600-1000 ng/dL)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No exercise (non-PRT group)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 167
Study: 20546622

Group type: EXPERIMENTAL
Intervention: Anti-platelet drug use (50% of diabetic patients)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Platelet inhibitor use (including aspirin and non-aspirin)
Number of subjects: 1007
Study: 18811599

Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 mg once daily (up-titrated to 15 mg after 2 weeks if needed) for up to 12 weeks
Number of subjects: 497
Study: 16329997

Group type: EXPERIMENTAL
Intervention: OX40 gene variants (specifically polymorphism in intron 5, rs2298212)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic variation (rs2298211) linked to intronic variant
Number of subjects: 0
Study: 12542559

Group type: EXPERIMENTAL
Intervention: GIK infusion
Number of subjects: 33

Group type: COMPARATOR
Intervention: MIT
Number of subjects: 33
Study: 10584288

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 0
Study: 7755069

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 gm every 8 hours)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 2097485

Group type: EXPERIMENTAL
Intervention: Fentanyl 20 micrograms (0.4 ml) with 0.5% heavy marcaine 2.0 ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group: 0.5% heavy marcaine 2.0 ml with CSF 0.4 ml
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 6457568

Group type: EXPERIMENTAL
Intervention: 2% solution of erythromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blank vehicle
Number of subjects: 0
Study: 30345963

Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stainless steel crowns (SSCs)
Number of subjects: 50
Study: 27119575

Group type: COMPARATOR
Intervention: PD 0348292 (2.5-150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PD 0348292 (5-30 mg) every 12 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: PD 0348292 (5 mg) single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PD 0348292
Number of subjects: 0